The Chinese Government’s wide-ranging bribery and corruption investigation into the pharmaceutical industry takes a new turn every week. Media reports contain numerous incidents of purported whistleblowers making allegations...more
The Chinese government’s recent crackdown on alleged bribery and corruption of local officials by multinational pharmaceutical companies could signal a broad trend toward elevated scrutiny of all foreign corporations...more
McDermott Will & Emery is pleased to offer “Distribution in China – Legal Issues*,” a one-stop resource covering distribution in China, including:
The business models and legal structures most commonly used for...more
4/4/2013
/ Bribery ,
Business Taxes ,
China ,
Compliance ,
Contract Drafting ,
Covenant of Good Faith and Fair Dealing ,
Customs ,
Distributors ,
E-Commerce ,
Exports ,
Foreign Corrupt Practices Act (FCPA) ,
Foreign Investment ,
Franchises ,
Imports ,
Joint Venture ,
Price-Fixing ,
Private Equity ,
Retailers ,
Trademarks ,
UK Bribery Act ,
Unfair Competition ,
Wholesale